Improving Health Outcomes in Patients with ATTR-CM Through the Development of a Shared Decision-Making Tool (Decision Aid)
Funds research to develop, validate, and evaluate a shared decision-making tool to improve care and outcomes for patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
Funder: Pfizer Inc.
Due Dates: May 5, 2026 | June 3, 2026
Funding Amounts: Up to $250,000 USD per project; 1-year maximum duration; 28% overhead cap applies.
Summary: Supports the development and validation of a shared decision-making tool to improve outcomes for patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
Key Information: Only organizations (not individuals) are eligible; U.S. and select global applicants permitted; late submissions not accepted.
Description
This grant opportunity funds the creation, validation, and evaluation of a shared decision-making tool (Decision Aid) to enhance decision quality, health outcomes, patient experience, and quality of care for individuals with transthyretin amyloid cardiomyopathy (ATTR-CM). The initiative emphasizes collaboration between medical societies or professional organizations and patient advocacy groups, ensuring the tool is co-developed with input from patients, caregivers, and healthcare professionals. Projects should address gaps and challenges in the ATTR-CM care pathway, incorporate needs assessments, and utilize rigorous design and validation methodologies. The final tool should be practical, relevant, and facilitate meaningful patient-clinician dialogue.
